MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

Size: px
Start display at page:

Download "MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia."

Transcription

1 ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Congenital, familial and genetic disorders Ear and labyrinth disorders Agranulocytosis Anaemia Aplastic anaemia Eosinophilia Febrile neutropenia Leukocytosis Leukopenia Lymphadenopathy Lymphopenia Neutropenia Pancytopenia Thrombocythaemia Thrombocytopenia Bradycardia Cardiac arrest Cardiac disorder Cardiomegaly Cardiomyopathy Cyanosis Extrasystoles Left ventricular failure Myocarditis Palpitations Tachycardia Congenital foot malformation Deafness Ototoxicity Tinnitus Page 1

2 Endocrine disorders Cushing's syndrome Eye disorders Gastrointestinal disorders Hyperthyroidism Hypothyroidism Inappropriate antidiuretic hormone secretion Blepharitis Blepharospasm Cataract Cataract subcapsular Eye disorder Eye pain Glaucoma Lens disorder Miosis Mydriasis Oculogyration Retinal pigmentation Visual acuity reduced Visual disturbance Abdominal pain Aphthous stomatitis Cheilitis Constipation Dry mouth Dysphagia Faecal incontinence Faeces discoloured Gastrointestinal haemorrhage Glossitis Haematemesis Megacolon Melaena Mouth ulceration Nausea Pancreatitis Salivary hypersecretion Page 2

3 Gastrointestinal disorders Swollen tongue General disorders and administration site conditions Hepatobiliary disorders Tongue oedema Vomiting Chest pain Chills Drug ineffective Drug withdrawal syndrome Drug withdrawal syndrome neonatal Face oedema Fatigue Feeling abnormal Gait disturbance Hyperpyrexia Hypothermia Influenza like illness Injection site inflammation Injection site necrosis Injection site reaction Irritability Malaise Oedema Oedema peripheral Pain Paradoxical drug reaction Pyrexia Sudden death Thirst Hepatic cirrhosis Hepatic failure Hepatic function abnormal Hepatitis Hepatitis cholestatic Hepatocellular damage Hepatomegaly Jaundice Page 3

4 Hepatobiliary disorders Jaundice cholestatic Immune system disorders Infections and infestations Anaphylactoid reaction Abscess Candidiasis Cellulitis Injection site abscess Pharyngitis Pneumonia Rash pustular Rhinitis Sepsis Upper respiratory tract infection Injury, poisoning and procedural complicatio Fall Investigations Metabolism and nutrition disorders Blood alkaline phosphatase increased Blood creatine phosphokinase increased Blood pressure decreased Blood thyroid stimulating hormone increased Ejection fraction decreased Electrocardiogram abnormal Electrocardiogram QT prolonged Hepatic enzyme increased Liver function test abnormal Oxygen saturation decreased Prothrombin level decreased Red blood cell sedimentation rate increased Troponin increased Urine analysis abnormal Weight decreased Weight increased Anorexia Hyperglycaemia Hyperkalaemia Hypocalcaemia Hypokalaemia Hyponatraemia Page 4

5 Metabolism and nutrition disorders Ketosis Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecif Nervous system disorders Obesity Polydipsia Arthralgia Muscle necrosis Muscle twitching Musculoskeletal stiffness Myalgia Rhabdomyolysis Systemic lupus erythematosus Torticollis Breast cancer female Akathisia Amnesia Brain oedema Cerebral haemorrhage Coma Consciousness fluctuating Convulsion Convulsion neonatal Coordination abnormal Depressed level of consciousness Disturbance in attention Dizziness Dysarthria Dysgeusia Dyskinesia Dystonia Encephalopathy Extrapyramidal disorder Grand mal convulsion Headache Hemiparesis Hyperkinesia Hyperreflexia Page 5

6 Nervous system disorders Hypertonia Pregnancy, puerperium and perinatal conditions Psychiatric disorders Hypoaesthesia Hypokinesia Lethargy Neuroleptic malignant syndrome Neuropathy peripheral Paraesthesia Sedation Sensory disturbance Serotonin syndrome Somnolence Speech disorder Syncope Tardive dyskinesia Tongue paralysis Tremor Unresponsive to stimuli Intra-uterine death Neonatal disorder Aggression Agitation Anxiety Catatonia Completed suicide Confusional state Delirium Depersonalisation Depression Disorientation Frustration Hallucination Homicidal ideation Insomnia Libido decreased Mania Page 6

7 Psychiatric disorders Nervousness Renal and urinary disorders Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Nightmare Personality change Psychotic disorder Restlessness Suicidal ideation Suicide attempt Thinking abnormal Anuria Choluria Dysuria Haematuria Myoglobinuria Nephritis interstitial Renal failure acute Renal impairment Renal tubular necrosis Urinary incontinence Urinary retention Breast enlargement Erectile dysfunction Galactorrhoea Priapism Apnoea Cough Dysphonia Dyspnoea Epistaxis Hyperventilation Productive cough Pulmonary hypertension Pulmonary oedema Respiratory depression Sinus congestion Throat tightness Page 7

8 Respiratory, thoracic and mediastinal disord Wheezing Skin and subcutaneous tissue disorders Acne Alopecia Angioedema Blister Cold sweat Dermatitis Dermatitis bullous Dermatitis contact Dermatitis psoriasiform Dry skin Eczema Erythema Erythema multiforme Hyperhidrosis Melanosis Periorbital oedema Photosensitivity reaction Pruritus Purpura Rash Rash erythematous Rash macular Rash maculo-papular Rash morbilliform Rash papular Seborrhoea Seborrhoeic dermatitis Skin discolouration Skin disorder Skin exfoliation Skin necrosis Skin swelling Skin ulcer Toxic epidermal necrolysis Page 8

9 Skin and subcutaneous tissue disorders Urticaria Vascular disorders Circulatory collapse Flushing Hypertension Hypotension Orthostatic hypotension Pallor Page 9

Medicine summary - Antipsychotics- chlorpromazine

Medicine summary - Antipsychotics- chlorpromazine 591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis

More information

Medicine summary - Antipsychotics- haloperidol

Medicine summary - Antipsychotics- haloperidol 748 22 330 Blood and lymphatic system disorders Anaemia 2 0 0 Bone marrow failure 1 0 0 Pancytopenia 4 0 1 Haemolytic anaemia 1 0 0 Thrombocytopenia 2 0 0 Lymphadenopathy 1 0 0 Splenomegaly 2 0 0 Eosinophilia

More information

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic

More information

Medicine summary - citalopram (to end January 2009)

Medicine summary - citalopram (to end January 2009) 734 13 493 Blood and lymphatic system disorders Iron deficiency anaemia 1 0 1 Anaemia 1 0 1 Pancytopenia 2 0 0 Thrombocytopenia 3 0 2 Lymphadenopathy 1 0 1 Eosinophilia 2 0 1 Leukocytosis 1 0 0 Leukopenia

More information

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Case Series Drug Analysis Print Name: Isotretinoin

Case Series Drug Analysis Print Name: Isotretinoin Report Run Date: 30-Dec-2013 Data Lock Date: 27-Dec-2013 23:09:23 Earliest Reaction Date: 12-Jun-1997 MedDRA Version: MedDRA 16.1 Isotretinoin: No description provided. Report Run Date: 30-Dec-2013, Page

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR:

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR: M0BCore Safety Profile Active substance: Glatiramer Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg P-RMS: UK/H/PSUR/0027/002 Date of FAR: 20.03.2013 4.2 Posology

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 2 medicines between 01/01/2000 18/10/2017: Invokana (Canagliflozin) Not specified (Canagliflozin) Commonwealth of Australia

More information

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation

More information

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR: 0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

Continence PGD - Oxybutynin 5mg Modified Release

Continence PGD - Oxybutynin 5mg Modified Release Continence PGD - Oxybutynin 5mg Modified Release Patient group direction for the supply of Oxybutynin Lyrinel XL 5mg and 10mg tablets, maximum dose of 20mg/day to patients suffering from urinary frequency,

More information

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary and Mandatory Reports on 5-Hour Energy,

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR: Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015 Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data

More information

GLUCOSE TESTING-BLOOD

GLUCOSE TESTING-BLOOD 648.83 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, ANTEPARTUM CONDITION OR 648.84 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, POSTPARTUM

More information

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age :

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age : Case Number : 231711 9/8/27 M 36Y Unknown Urticaria Reason : Tablet 4 Milligram 2 times Oral CITALOPRAM HYDROBROMIDE (Other drug) Reason : 4 Milligram Oral PUTRAN2 Page 1 of 18 Case Number : 233954 M 3/1/27

More information

Statin Adverse Reactions in the CARM database

Statin Adverse Reactions in the CARM database New Zealand Pharmacovigilance Centre University of Otago PO Box 913, Dunedin, New Zealand Telephone: 64-3-479 7185 Fax: 64-3-479 7150 Email: nzphvc@otago.ac.nz Website: www.otago.ac.nz/carm Report Title:

More information

Statin Adverse Reactions in the CARM database

Statin Adverse Reactions in the CARM database New Zealand Pharmacovigilance Centre University of Otago PO Box 913, Dunedin, New Zealand Telephone: 64-3-479 7185 Fax: 64-3-479 7150 Email: nzphvc@otago.ac.nz Website: www.otago.ac.nz/carm Report Title:

More information

4.4 Special warnings and precautions for use

4.4 Special warnings and precautions for use SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

UK Suspected Adverse Drug Reaction (ADR) Analysis

UK Suspected Adverse Drug Reaction (ADR) Analysis UK Suspected Adverse Drug Reaction (ADR) Analysis Influenza antivirals - oseltamivir (Tamiflu) and zanamivir (Relenza) 26 th November 2009 This report summarises all UK reports of suspected adverse drug

More information

Psychotherapeutic drugs

Psychotherapeutic drugs Psychotherapeutic drugs Drugs used in psychotic disorders Treatment of psychotic disorders is both pharmacological and psychosocial. Individual and community programmes for relearning old skills and developing

More information

CSP Nabumetone ES/H/PSUR/0014/001. January 2010

CSP Nabumetone ES/H/PSUR/0014/001. January 2010 CSP Nabumetone ES/H/PSUR/0014/001 January 2010 CLINICAL PARTICULARS 4.1 Therapeutic indications Nabumetone is indicated in the symptomatic treatment of a variety of musculoskeletal disorders requiring

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. Protein Kinase Inhibitor (L01XE23)

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. Protein Kinase Inhibitor (L01XE23) PRODUCT MONOGRAPH Pr MEKINIST Trametinib Tablets 0.5 mg and 2 mg Protein Kinase Inhibitor (L01XE23) Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 Date of Revision: May

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION * CAVEAT: The vast majority of reports on which this summary is based are submitted by health practitioners. Each report represents the suspicion, opinion or observation of the individual reporter. Cause

More information

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1 Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy

More information

1.1. An overview of reports on sitagliptin

1.1. An overview of reports on sitagliptin 1.1. An overview of reports on Introduction Sitagliptin (Januvia ) was registered for the European marked on March 21 st 27 with the Netherlands as rapporteur. It is indicated as treatment of for patients

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

APPROVED PACKAGE INSERT

APPROVED PACKAGE INSERT APPROVED PACKAGE INSERT SCHEDULING STATUS:S3 PROPRIETARY NAMES (AND DOSAGE FORMS): PONSTAN (CAPSULES) PONSTAN FORTE (TABLET) PONSTAN (SUSPENSION) PONSTAN (PAEDIATRIC SUPPOSITORIES) COMPOSITION: PONSTAN

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR: M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity

More information

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DARZALEX daratumumab 20 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic, monoclonal antibody Janssen Inc. 19

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

0BCore Safety Profile

0BCore Safety Profile 0BCore Safety Profile Active substance: Chlorpromazine Pharmaceutical form(s)/strength: 10mg, 25mg, 50mg and 100mg fim-coated or uncoated tablets 5mg/ml syrup, 10mg/ml and 20mg/ml suspension forte, 40mg/ml

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: DEMAZIN NS REPETABS COMPOSITION: Active Ingredients: Each DEMAZIN NS REPETAB contains 5 mg loratadine (micronised) in the tablet coating and 120

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR: Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DARZALEX daratumumab 20 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic, monoclonal antibody DARZALEX, indicated

More information

PhUSE. PhUSE Computational Science Standard Analyses and Code Sharing Working Group

PhUSE. PhUSE Computational Science Standard Analyses and Code Sharing Working Group PhUSE PhUSE Computational Science Standard Analyses and Working Group Script Discovery and Acquisition Project Team Screen Shots of the Displays Created Using Scripts 1 Table of Contents 1. Disclaimer...

More information

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy PRODUCT MONOGRAPH Pr MYOZYME alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial Enzyme Replacement Therapy Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.

More information

TILAZEM. Diltiazem hydrochloride 240 mg

TILAZEM. Diltiazem hydrochloride 240 mg Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)

More information

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash

More information

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This

More information

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor PRODUCT MONOGRAPH Pr MEKINIST Trametinib Tablets 0.5 mg and 2 mg ATC Code: L01XE23 Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. Date of Revision: 385 Bouchard Blvd. September 21, 2018

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bryan P, Seabroke S, Wong J, et al. Safety

More information

MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h.

MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h. PRODUCT MONOGRAPH Pr MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h. Pr MYLAN-RIVASTIGMINE PATCH 10

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:

More information

GLUCOSE TESTING-BLOOD

GLUCOSE TESTING-BLOOD Abnormal glucose tolerance complicating pregnancy, childbirth or the 648.83 puerperium, antepartum condition or complication Abnormal glucose tolerance complicating pregnancy, childbirth or the 648.84

More information

Buserelin Non European. European Economic Area

Buserelin Non European. European Economic Area Blood Card Cong Ear Endo Eye Non Anaemia 2 1 3 Aplastic anaemia 0 2 2 Eosinophilia 0 1 1 Haemolysis 1 0 1 Haemorrhagic disorder 0 1 1 Leukopenia 1 2 3 Thrombocytopenia 0 10 10 Angina pectoris 0 2 2 Arrhythmia

More information

Annex I CORE SAFETY PROFILE. Trazodone hydrochloride TRITTICO

Annex I CORE SAFETY PROFILE. Trazodone hydrochloride TRITTICO Annex I CORE SAFETY PROFILE Trazodone hydrochloride TRITTICO 4.1 Therapeutic indications [Depressive disorders with or without anxiety.] 1 [Supportive treatment of pain. Enhancement of anesthesia.] 2 4.2

More information

Supplementary materials for:

Supplementary materials for: Supplementary materials for: Cecil E, Bottle A, Sharland M, Saxena S. Impact of UK primary care policy reforms on short-stay unplanned hospital admissions for children with primary care-sensitive conditions.

More information

OXYSPAS Tablets (Oxybutynin chloride)

OXYSPAS Tablets (Oxybutynin chloride) Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains

More information

DNA CENTER New Patient Information

DNA CENTER New Patient Information DNA CENTER New Patient Information Name Email: Address City State Zip Home Phone Work Cell Phone Social Security Number Date of birth Gender ( Male/Female) Age Please Circle: Hispanic/Latin or Non Hispanic/Latin

More information

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425) IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:

More information

Headache Follow-up Visit Form

Headache Follow-up Visit Form !1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:

More information

RISPERDAL (risperidone)

RISPERDAL (risperidone) RISPERDAL (risperidone) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RISPERDAL safely and effectively. See full prescribing information for RISPERDAL.

More information

P-RMS: FR/H/PSUR/0036/001

P-RMS: FR/H/PSUR/0036/001 Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,

More information

Pregabalin (Prepentin)

Pregabalin (Prepentin) Korea United Pharm. Inc. Pregabalin (Prepentin) 75 mg, 150 mg CAPSULE Anticonvulsant Manufactured by: KOREA UNITED PHARM. INC. Imported/Distributed by: MACROPHARMA CORPORATION GENERIC NAME PREGABALIN IUPAC

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have

More information

1.1. An overview of reports on agomelatine

1.1. An overview of reports on agomelatine 1.1. An overview of reports on agomelatine Introduction Agomelatine (Valdoxan ) was registered for the European market on February 19th 2009 and is indicated for treatment of major depressive episodes

More information

Product Information VALOID. VALOID injection contains 50 mg/1 ml cyclizine lactate and has the following structural formula:

Product Information VALOID. VALOID injection contains 50 mg/1 ml cyclizine lactate and has the following structural formula: Product Information VALOID NAME OF THE MEDICINE VALOID injection contains 50 mg/1 ml cyclizine lactate and has the following structural formula: Molecular formula Molecular weight 266 CAS no. 82-92-8 C18H22N2

More information

Please note that the information highlighted in grey colour is the additional information specific to the concerned dosage form.

Please note that the information highlighted in grey colour is the additional information specific to the concerned dosage form. Proposed Core Safety Profile for diclofenac systemic formulations, including solution for injection, sugar-coated tablets, prolonged release tablets, dispersible tablets, gastro-resistant tablets and suppositories

More information

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze

More information

P-RMS: UK/H/PSUR/0051/001

P-RMS: UK/H/PSUR/0051/001 Core Safety Profile Active substance: Levofloxacin Pharmaceutical form(s)/strength: Film-coated tablets 250mg, 500mg Solution for infusion, 5mg/ml P-RMS: UK/H/PSUR/0051/001 Date of FAR: 01.04.2011 CORE

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg

Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg 4.2 Posology and method of administration Children and adolescents Chlorprothixene is not recommended for use in children

More information

Case Series Drug Analysis Print Name: DTPa IPV HIB

Case Series Drug Analysis Print Name: DTPa IPV HIB Report Run Date: 20-Feb-2014 Data Lock Date: 18-Feb-2014 01:01:22 Earliest Reaction Date: 02-Oct-2002 MedDRA Version: MedDRA 16.1 DTPa IPV HIB: Drug Analysis Print Report Run Date: 20-Feb-2014, Page 1

More information

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C.

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. Past Medical History AIDS/HIV disease Anemia Asthma Bronchitis Cancer Date of last Chest X-ray Diabetes Mellitus, Type I Diabetes Mellitus,

More information

PRODUCT MONOGRAPH. Pr Vectibix. (panitumumab) Sterile Solution for Infusion 100, 400 mg (20 mg/ml) Professed Standard.

PRODUCT MONOGRAPH. Pr Vectibix. (panitumumab) Sterile Solution for Infusion 100, 400 mg (20 mg/ml) Professed Standard. PRODUCT MONOGRAPH Pr Vectibix (panitumumab) Sterile Solution for Infusion 100, 400 mg (20 mg/ml) Professed Standard Antineoplastic Amgen Canada Inc. 6775 Financial Drive, Suite 100 Mississauga, Ontario

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. UROMITEXAN 400 mg and 600 mg Tablets Mesna

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. UROMITEXAN 400 mg and 600 mg Tablets Mesna PACKAGE LEAFLET: INFORMATION FOR THE PATIENT UROMITEXAN 400 mg and 600 mg Tablets Mesna Read all of this leaflet carefully before you are given this medicine because it contains important information for

More information